Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States
Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States
复制标题
DOI：
10.1111/ajt.16079
复制
发表时间：
2020-07-17
影响因子：
8.8
通讯作者：
Babik, Jennifer M.
中科院分区：
文献类型：
--
作者：
Fung, Monica;Chiu, Charles Y.;Babik, Jennifer M.
由 SARS 冠状病毒 2 (SARS-CoV-2) 引起的 2019 年冠状病毒病 (COVID-19) 大流行已导致患者显着发病和死亡，并给全世界的医疗保健系统带来压力。免疫抑制患者（例如实体器官移植（SOT）接受者）中的 COVID-19 的临床特征、病程和血清学反应尚未明确，这些患者被认为有患更严重疾病的风险。我们描述了我们在 10 名 SOT 患者中处理 COVID-19 的机构经验，包括 7 名肾移植受者、1 名肝移植受者、1 名心脏移植受者和 1 名肺移植受者的临床表现、治疗方式和结果。此外，我们报告了 SOT 接受者的血清学反应，记录了所有 7 名住院患者的 IgG 阳性反应。我们还回顾了有关 SOT 受者中的 COVID-19 的现有文献，以巩固移植界关于 SOT 人群中的 COVID-19 的当前知识。
The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among 10 SOT patients, including the clinical presentation, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all 7 hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.